A multi-institutional team led by Northwestern University demonstrated an implantable “living pharmacy” device that can continuously produce multiple biologics inside the body. In a study published in Device, the researchers engineered cells to simultaneously express an anti-HIV antibody, a GLP-1-like peptide for type 2 diabetes, and leptin. When implanted under the skin of a small animal model, the device supported cell viability and stable multi-product delivery over time. The approach represents a modular strategy for achieving in vivo protein production, potentially shifting parts of biologics manufacturing from external production lines to cellular factories within patients. If translated, the work could open new routes for maintaining therapeutic levels without repeated dosing, though further preclinical validation and long-term safety evaluation would be needed before clinical consideration.